INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 417m ago
HOUSE PTR17m ago
SEC 13F17m ago
ROBINHOOD CHAIN17m ago
SEC FORM 4/Grant or awardVerified data

Suseck Mark reported IBO

Chief Operating Officer · IMPACT BIOMEDICAL INC. · Common Stock

Side
A
Value
$19K
Shares
4,170
Price
$4.54
Executed
Oct 7, 2026
Disclosed
Nov 5, 2026
Disclosure timeline29 days from execution to publication · legal deadline 2 business days
Oct 7 executedNov 5, 2026 disclosed

IBO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
23/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+5 / 25

$19K reported value · 14.9% of prior position

  • Filing timing+10 / 15

    Disclosed 21 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IBO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    27
    MD
    Macko Todd DChief Financial Officer
    IBOIMPACT BIOMEDICAL INC.
    Grant or award
    		A$19K
    4,170 sh
    		Oct 7, 2026Nov 5, 2026
    traded Oct 7, 2026
    		+29dSEC FORM 4

    Evidence

    23
    ZT
    Zimmerman Christian ThomasDirector
    IBOIMPACT BIOMEDICAL INC.
    Grant or award
    		A$19K
    4,170 sh
    		Oct 7, 2026Nov 5, 2026
    traded Oct 7, 2026
    		+29dSEC FORM 4

    Evidence

    23
    HB
    Hibbert Castel BerisfordDirector
    IBOIMPACT BIOMEDICAL INC.
    Grant or award
    		A$19K
    4,170 sh
    		Oct 7, 2026Nov 5, 2026
    traded Oct 7, 2026
    		+29dSEC FORM 4

    Evidence

    23
    SK
    Sims Melissa KayeDirector
    IBOIMPACT BIOMEDICAL INC.
    Grant or award
    		A$19K
    4,170 sh
    		Oct 7, 2026Nov 5, 2026
    traded Oct 7, 2026
    		+29dSEC FORM 4

    Evidence

    23
    KK
    Keene David KDirector
    IBOIMPACT BIOMEDICAL INC.
    Grant or award
    		A$19K
    4,170 sh
    		Oct 7, 2026Nov 5, 2026
    traded Oct 7, 2026
    		+29dSEC FORM 4

    Evidence

    23
    BE
    Brownell EliseDirector
    IBOIMPACT BIOMEDICAL INC.
    Grant or award
    		A$19K
    4,170 sh
    		Oct 7, 2026Nov 5, 2026
    traded Oct 7, 2026
    		+29dSEC FORM 4

    Evidence

    23
    CA
    Chan Heng Fai AmbroseDirector, 10% Owner
    IBOIMPACT BIOMEDICAL INC.
    Grant or award
    		A$19K
    4,170 sh
    		Oct 7, 2026Nov 5, 2026
    traded Oct 7, 2026
    		+29dSEC FORM 4

    Evidence

    23
    GJ
    Grady JasonDirector
    IBOIMPACT BIOMEDICAL INC.
    Grant or award
    		A$19K
    4,170 sh
    		Oct 7, 2026Nov 5, 2026
    traded Oct 7, 2026
    		+29dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001493152-26-050296
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 7, 2026
    Published
    Nov 5, 2026
    Ingested by INSIDER
    Nov 6, 03:18 UTC
    Last re-read
    Nov 6, 09:18 UTC

    Extracted facts

    Filer
    Suseck Mark
    Role
    Chief Operating Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    IMPACT BIOMEDICAL INC.
    Ticker
    IBO
    Shares
    4,170
    Price per share
    $4.54
    Value
    $18,932
    Execution date (reported)
    Oct 7, 2026
    Owned after transaction
    32.1K shares
    Days from execution to publication
    29

    Calculation

    Value = shares × reported price per share

    • Shares: 4,170
    • Price: $4.54

    = $18,932

    What this establishes

    Suseck Mark filed this Form 4 reporting a grant or award of IBO on Oct 7, 2026. It became public on Nov 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Operating Officer
    Suseck Markcik:0002033773
    Issuer
    IMPACT BIOMEDICAL INC.cik:0001834105

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.